Tags

Type your tag names separated by a space and hit enter

Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.
J Med Virol. 2021 04; 93(4):1967-1982.JM

Abstract

The year 2020 started with the emergence of novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes COVID-19 infection. Soon after the first evidence was reported in Wuhan, China, the World Health Organization declared global public health emergency and imminent need to understand the pathogenicity of the virus was required in limited time. Once the genome sequence of the virus was delineated, scientists across the world started working on the development of vaccines. Although, some laboratories have been using previously developed vaccine platforms from severe acute respiratory syndrome coronavirus (SARS) and middle east respiratory syndrome-related coronavirus and apply them in COVID-19 vaccines due to genetic similarities between coronaviruses. We have conducted a literature review to assess the background and current status of COVID-19 vaccines. The worldwide implementation and strategies for COVID-19 vaccine development are summarized from studies reported in years 2015-2020. While discussing the vaccine candidates, we have also explained interpretative immune responses of SARS-CoV-2 infection. There are several vaccine candidates at preclinical and clinical stages; however, only 42 vaccines are under clinical trials. Therefore, more industry collaborations and financial supports to COVID-19 studies are needed for mass-scale vaccine development. To develop effective vaccine platforms against SARS-CoV-2, the genetic resemblance with other coronaviruses are being evaluated which may further promote fast-track trials on previously developed SARS-CoV vaccines.

Authors+Show Affiliations

Amity Institute of Nanotechnology (AINT), Amity University Uttar Pradesh (AUUP), Noida, India.Amity Institute of Nanotechnology (AINT), Amity University Uttar Pradesh (AUUP), Noida, India.Amity Institute of Nanotechnology (AINT), Amity University Uttar Pradesh (AUUP), Noida, India.Rahat Hospital and Research Centre, Noor Mahal, AVAS Vikas, Rampur, India.Amity Institute of Nanotechnology (AINT), Amity University Uttar Pradesh (AUUP), Noida, India.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Systematic Review

Language

eng

PubMed ID

33270225

Citation

Chauhan, Nidhi, et al. "Interpretative Immune Targets and Contemporary Position for Vaccine Development Against SARS-CoV-2: a Systematic Review." Journal of Medical Virology, vol. 93, no. 4, 2021, pp. 1967-1982.
Chauhan N, Soni S, Gupta A, et al. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review. J Med Virol. 2021;93(4):1967-1982.
Chauhan, N., Soni, S., Gupta, A., Aslam, M., & Jain, U. (2021). Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review. Journal of Medical Virology, 93(4), 1967-1982. https://doi.org/10.1002/jmv.26709
Chauhan N, et al. Interpretative Immune Targets and Contemporary Position for Vaccine Development Against SARS-CoV-2: a Systematic Review. J Med Virol. 2021;93(4):1967-1982. PubMed PMID: 33270225.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review. AU - Chauhan,Nidhi, AU - Soni,Shringika, AU - Gupta,Abhinandan, AU - Aslam,Mohammad, AU - Jain,Utkarsh, Y1 - 2020/12/17/ PY - 2020/10/11/received PY - 2020/11/29/accepted PY - 2020/12/4/pubmed PY - 2021/3/6/medline PY - 2020/12/3/entrez KW - Antiviral agents KW - Coronavirus KW - Immnopathology KW - Immunodulators KW - Respiratory tract KW - pandemic SP - 1967 EP - 1982 JF - Journal of medical virology JO - J Med Virol VL - 93 IS - 4 N2 - The year 2020 started with the emergence of novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes COVID-19 infection. Soon after the first evidence was reported in Wuhan, China, the World Health Organization declared global public health emergency and imminent need to understand the pathogenicity of the virus was required in limited time. Once the genome sequence of the virus was delineated, scientists across the world started working on the development of vaccines. Although, some laboratories have been using previously developed vaccine platforms from severe acute respiratory syndrome coronavirus (SARS) and middle east respiratory syndrome-related coronavirus and apply them in COVID-19 vaccines due to genetic similarities between coronaviruses. We have conducted a literature review to assess the background and current status of COVID-19 vaccines. The worldwide implementation and strategies for COVID-19 vaccine development are summarized from studies reported in years 2015-2020. While discussing the vaccine candidates, we have also explained interpretative immune responses of SARS-CoV-2 infection. There are several vaccine candidates at preclinical and clinical stages; however, only 42 vaccines are under clinical trials. Therefore, more industry collaborations and financial supports to COVID-19 studies are needed for mass-scale vaccine development. To develop effective vaccine platforms against SARS-CoV-2, the genetic resemblance with other coronaviruses are being evaluated which may further promote fast-track trials on previously developed SARS-CoV vaccines. SN - 1096-9071 UR - https://www.unboundmedicine.com/medline/citation/33270225/Interpretative_immune_targets_and_contemporary_position_for_vaccine_development_against_SARS_CoV_2:_A_systematic_review_ L2 - https://doi.org/10.1002/jmv.26709 DB - PRIME DP - Unbound Medicine ER -